REG - N4 Pharma PLC - AGM Statement

N4 PharmaAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nRSd8592Oa&default-theme=true

RNS Number : 8592O  N4 Pharma PLC  30 June 2025

 

30 June 2025

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

AGM Statement

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary
gene delivery system to enable advanced therapies for cancer and other
diseases, will hold its Annual General Meeting (AGM) at 11.00 am today at Arch
Law Limited Huckletree Bishopsgate, 8 Bishopsgate, London, EC2N 4BQ.

Nigel Theobald, Chief Executive Officer, will provide the following statement:

"As outlined in the Company's final results early this month, I am pleased to
report that N4 Pharma continues to deliver strong technical and operational
progress, maintaining a clear strategic focus on advancing its Nuvec® RNA
delivery platform.

"RNA therapeutics remains a rapidly expanding field of global interest among
major pharmaceutical companies and biotech innovators, yet the central
challenge persists: how to deliver these therapies safely, effectively, and
intact to their target tissues. This is precisely where N4 Pharma believe
Nuvec® offers a unique and highly differentiated solution.

"Over the past year, Nuvec® has generated compelling pre-clinical data,
consistently meeting key performance benchmarks for next-generation RNA
delivery systems. These results reinforce the Company's belief in Nuvec®'s
potential to become a delivery platform of choice.

"In May 2025, building on positive data from the Company's first in vivo
efficacy study of N4 101 in a standard animal model of Inflammatory Bowel
Disease (IBD) and supported by a successful fundraising round in April 2025,
N4 Pharma launched an expanded work programme to strengthen the commercial
data package around Nuvec®.

"This enhanced programme, to be delivered over the next 12 to 18 months, is
being executed by a highly experienced team with deep expertise in both
science and commercialisation. It is focused on the following key data
packages that are designed to support future deal-making and add significant
shareholder value.

 ·   Oral delivery - Nuvec® protects SiRNA from degradation, which enables oral
     delivery to the GI tract. Oral delivery has significant advantages compared
     with other methods such as intrathecal injections and intravenous infusions,
     and, as yet, no orally delivered RNA therapeutic has been approved. N4 Pharma
     will expand the existing data set to demonstrate the performance of an orally
     delivered RNA therapeutic.

 ·   Endosomal release - getting the RNA into cells is one part of the process; the
     RNA then has to be released from the delivery vehicle for it to take effect.
     This is a very inefficient process with existing delivery platforms such as
     lipid nanoparticles, which typically release only a few per cent of the RNA.
     The planned work package aims to demonstrate a higher endosomal release for
     Nuvec® compared with lipid nanoparticles, which should lead to improved RNA
     delivery into the cytoplasm and increased therapeutic activity. This would be
     a significant competitive advantage for Nuvec® in the market.

 ·   Dual loading - loading of two RNA therapeutics allows delivery of two drugs in
     a single 'drug entity', with the potential to deliver more efficacious
     combination therapies, whilst only requiring a single set of toxic studies.
     Nuvec® is known to be able to deliver multiple RNA therapeutics, and this
     work programme aims to build out the existing data to demonstrate this key
     benefit of the Nuvec® platform.

 ·   CMC (Manufacturing) - it is essential that a delivery platform has
     class-leading performance as well as being straightforward and reproducible to
     manufacture. Nuvec® has been shown to be simple to manufacture, and this work
     package will now focus on improving yield and demonstrating sterile
     manufacture for human studies, which de-risks future development for a
     partner.

 ·   Targeting - the RNA to specific cell types or tissues is the holy grail of RNA
     therapeutics because it reduces off-target effects and improves efficacy. All
     RNA therapeutics developers would wish to target their drug products to
     specific tissues. Early work at N4 Pharma has shown that Nuvec® particles can
     be modified on their surface to target particular cells, and this work package
     will expand on this critical data set that will set Nuvec® apart from all
     other delivery platforms.

 ·   Toxicity - existing delivery platforms such as viral vectors and lipid
     nanoparticles have poor in vivo tolerability profiles.  Nuvec® is made of
     silica, which is known to be benign from a toxicity perspective.  This work
     package will demonstrate good in vivo tolerability in a number of models,
     which again significantly de-risks future development for a partner.

 ·   Pharmacokinetics and Biodistribution - it is critical that any drug gets to
     the site of action, remaining there long enough to have a durable effect, and
     that remaining drug or metabolites are excreted safely. This work package aims
     to measure, using standard techniques, the behaviour of Nuvec® particles in
     vivo to demonstrate an appropriate PK profile for RNA drugs.

"This next phase of work, building out the data packages that the Company has,
is critical to achieving N4 Pharma's near-term goal: securing licensing
agreements with third-party partners and enabling Nuvec® to be integrated
into external RNA drug development pipelines.

"Each data package, when complete, will move N4 Pharma along the value curve,
delivering increasing value to shareholders over the coming months.

"At the same time, the programme lays the foundation for the
Company's longer-term ambition to develop a proprietary pipeline of RNA-based
therapeutics that are both differentiated and enabled by the Nuvec®
platform. These two parallel paths represent significant opportunities for
near and long-term value creation.

"On behalf of the Board, I would like to thank N4 Pharma's shareholders for
their continued support. Nuvec® represents a transformational
opportunity for N4 Pharma, and the Company is focused on executing its
strategy designed to deliver an increase in shareholder value both in the near
and longer term. We look forward to providing further updates as N4 Pharma
moves through this exciting and pivotal phase of development."

- Ends -

 

N4 Pharma Insight Event for Retail Investors

As announced on 25 June 2025, N4 Pharma will host an Investor Insight
Event for retail investors on Monday, 14 July 2025, at the Royal College of
Surgeons, 38-43 Lincoln's Inn Fields, London, WC2A 3PE, from 10.00 am until
12.00 pm. The event will include a Q&A session, offering investors the
opportunity to engage directly with the executive team. This will be followed
by a networking lunch, where attendees can meet other members of the Board
and senior management.

 

To register for the event, please contact sarah@northstarcommunications.co.uk
(mailto:sarah@northstarcommunications.co.uk)

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                                       Via N4 Pharma Investor Hub: investors.n4pharma.com

                                                                         (https://investors.n4pharma.com/)
 Luke Cairns, Executive Director

                                                                         https://investors.n4pharma.com/link/qy1wAr
 Submit your questions directly to the management team via the N4 Pharma   (https://investors.n4pharma.com/link/qy1wAr)
 Investor Hub

 SP Angel Corporate Finance LLP                                            Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Jen Clarke (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                                     Tel: +44 (0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope
 Northstar Communications Limited                                          Tel: +44 (0)113 730 3896

 Investor Relations

 Sarah Hollins

 

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its
proprietary gene delivery system, to enable advanced therapies for cancer and
other diseases.

 

RNA therapeutics are set to impact the treatment of a wide range of diseases
and Nuvec® has several key advantages for RNA gene delivery including the
ability to deliver multiple RNA therapies in a single particle, ease of
manufacturing, protection of the RNA payload to allow for oral delivery, no
unwanted immune response and excellent stability and storage.

 

N4 Pharma is building out its preclinical data set and working towards
first-in-human clinical data to support significant licensing deals for its
Nuvec® platform with gene therapy partners.

 

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for
IBD which serves as a proof-of-concept programme showcasing all the benefits
of the Nuvec® platform.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at
https://investors.n4pharma.com/auth/signup
(https://investors.n4pharma.com/auth/signup) .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMBSGDLXDDDGUC